Science Explorer Back to mapMap

Most cited papers from Cel-Sci (United States)

What are the most cited papers from Cel-Sci (United States)?

The most cited paper from Cel-Sci (United States) is "Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models" (Adrienn Markovics, Ken S. Rosenthal, Katalin Mikecz et al., 2021), with 58 citations. Next come "Vaccines: All Things Considered" (50) and "Design and Operational Performance of Double Crossover Intersection and Diverging Diamond Interchange" (49).

Showing 41 of 41 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models Adrienn Markovics, Ken S. Rosenthal, Katalin Mikecz et al. · Biomedicines Open access 26 Dec 2021 58
2 Vaccines: All Things Considered Ken S. Rosenthal, Daniel H. Zimmerman · Clinical and Vaccine Immunology Open access Aug 2006 50
3 Design and Operational Performance of Double Crossover Intersection and Diverging Diamond Interchange Joe G. Bared, Praveen K. Edara, Ramanujan Jagannathan · Transportation Research Record Journal of the Transportation Research Board 2005 49
4 Immunization with a LEAPS™ heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1 Ken S. Rosenthal, Hanwen Mao, Walter I. Horne et al. · Vaccine Feb 1999 46
5 CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model Daniel H. Zimmerman, Patricia Taylor, Alison M. Bendele et al. · International Immunopharmacology 15 Jan 2010 36
6 Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis Kenneth S. Rosenthal, Katalin Mikecz, Harold L Steiner et al. · Expert Review of Vaccines Open access 18 Mar 2015 33
7 Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine Vladimir M. Pisarev, Prahlad Parajuli, Rodney Lee Mosley et al. · International Journal of Immunopharmacology Nov 2000 24
8 An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis Katalin Mikecz, Tibor T. Glant, Adrienn Markovics et al. · Vaccine Open access 4 Jun 2017 22
9 The ability of an HSV strain to initiate zosteriform spread correlates with its neuroinvasive disease potential Neena Goel, Hongyi Mao, Q. Rong et al. · Archives of Virology Apr 2002 22
10 CEL-1000—a peptide with adjuvant activity for Th1 immune responses Yupin Charoenvit, Neena Goel, Michael Whelan et al. · Vaccine 9 Apr 2004 22
11 The Effect of Leukocyte Interleukin Injection (Multikine®) Treatment on the Peritumoral and Intratumoral Subpopulation of Mononuclear Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity to Radiation Therapy and Chemotherapy in Oral Cancer—A Multicenter Phase I/II Clinical Trial József Tı́már, Csaba Forster‐Horváth, Júlia Lukits et al. · The Laryngoscope Dec 2003 21
12 J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells Philip R. Taylor, Gary K. Koski, Christopher C. Paustian et al. · Vaccine 26 Jun 2010 21
13 Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens Patricia Taylor, Christopher C. Paustian, Gary K. Koski et al. · Cellular Immunology Open access 2010 17
14 Antigen-activated dendritic cells ameliorate influenza A infections Kobporn Boonnak, Leatrice Vogel, Marlene S. Orandle et al. · Journal of Clinical Investigation Open access 23 Jun 2013 17
15 The L.E.A.P.S. approach to vaccine development Hsu Daniel · Frontiers in bioscience Open access 2005 17
16 A New Oil-Based Antigen Delivery Formulation for both Oral and Parenteral Vaccination Marta de Oliveira Domingos, David J. M. Lewis, Theo Jansen et al. · The Open Drug Delivery Journal Open access 24 Jul 2008 16
17 Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine Vladimir M. Pisarev, Prahlad Parajuli, Rodney Lee Mosley et al. · Vaccine May 2002 16
18 J‐LEAPS peptide and LEAPS dendritic cell vaccines Ken S. Rosenthal, Patricia R. Taylor, Daniel H. Zimmerman · Microbial Biotechnology Open access 6 Sep 2011 16
19 A Small Peptide (CEL-1000) Derived from the β-Chain of the Human Major Histocompatibility Complex Class II Molecule Induces Complete Protection against Malaria in an Antigen-Independent Manner Yupin Charoenvit, Gary T. Brice, David Bacon et al. · Antimicrobial Agents and Chemotherapy Open access 23 Jun 2004 15
20 Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1SF2 p17) and peptide segments of human β-2-microglobulin or MHC II β chain Daniel H. Zimmerman, JOHN P. LLOYD, Daniel A.R. Heisey et al. · Vaccine Sep 2001 15
21 L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart Daniela Čiháková, Jobert G. Barin, G. Christian Baldeviano et al. · International Immunopharmacology Open access 30 Jan 2008 15
22 Vaccination by Two DerG LEAPS Conjugates Incorporating Distinct Proteoglycan (PG, Aggrecan) Epitopes Provides Therapy by Different Immune Mechanisms in a Mouse Model of Rheumatoid Arthritis Daniel H. Zimmerman, Katalin Mikecz, Adrienn Markovics et al. · Vaccines Open access 2 May 2021 14
23 A modification of the epidermal scarification model of herpes simplex virus infection to achieve a reproducible and uniform progression of disease Neena Goel, John J. Docherty, Ming Fu et al. · Journal of Virological Methods 21 Oct 2002 12
24 Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice Prem S. Sarin, James E. Talmadge, Peter N.R. Heseltine et al. · Vaccine 1999 12
25 LEAPS Therapeutic Vaccines as Antigen Specific Suppressors of Inflammation in Infectious and Autoimmune Diseases Daniel H. Zimmerman · Journal of Vaccines & Vaccination Open access 2012 10
26 Two Low-Cost Safety Concepts for Two-Way, Stop-Controlled Intersections in Rural Areas Frank B. Gross, Ram Jagannathan, Warren Hughes · Transportation Research Record Journal of the Transportation Research Board 2009 10
27 Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review. Ken S. Rosenthal, Roy E. Carambula, Daniel H. Zimmerman · PubMed Open access 2019 9
28 LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model Ken S. Rosenthal, Sarah Stone, Gary K. Koski et al. · Journal of Immunology Research Open access 2017 9
29 Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines Daniel H. Zimmerman, Zoltán Szekanecz, Adrienn Markovics et al. · Frontiers in Immunology Open access 6 Mar 2024 8
30 Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma –the IT-MATTERS study Eyal Talor, József Tı́már, Philip T. Lavin et al. · Pathology & Oncology Research Open access 21 Mar 2025 5
31 Lessons from next generation influenza vaccines for inflammatory disease therapies Daniel H. Zimmerman, Roy E. Carambula, Jason C. Ciemielewski et al. · International Immunopharmacology Open access 4 Jul 2019 5
32 Leukocyte Interleukin, INJ. (LI) Augmentation of Natural Killer Cells and Cytolytic T-Lymphocytes M. A. Chirigos, Eyal Talor, R. W. Sidwell et al. · Immunopharmacology and Immunotoxicology 1995 4
33 Road Safety Audits: FHWA Case Study Program Margaret S. Gibbs, Sany Zein, Dan Nabors et al. · Transportation Research Record Journal of the Transportation Research Board 2006 4
34 J-LEAPS vaccines elicit antigen specific Th1 responses by promoting maturation of type 1 dendritic cells (DC1) Ken S. Rosenthal, Daniel H. Zimmerman · AIMS Allergy and Immunology Open access 2017 3
35 Road Safety Audits Margaret S. Gibbs, Sany R. Zein, Dan Nabors et al. · Transportation Research Record Journal of the Transportation Research Board 2006 1
36 A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression The IT-MATTERS Clinical trial – Prognostic role of tumor PD-L1 expression Eyal Talor, Philip T. Lavin, John Cipriano et al. · Oral Oncology Open access 31 Jul 2026 0
37 893P Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma József Tı́már, Philip T. Lavin, John Cipriano et al. · Annals of Oncology Open access Oct 2023 0
38 690P Early response to leukocyte interleukin Injection (LI) immunotherapy extends overall survival (OS) in locally advanced primary squamous cell carcinoma of the head & neck (SCCHN): The IT-MATTERS study Phillip T. Lavin, Eyal Talor, D. Markovic et al. · Annals of Oncology Open access Sep 2022 0
39 Vaccine Immunomodulation of Disease: Targeting the Treatment of Autoimmune Diseases Ken S. Rosenthal, Daniel H. Zimmerman · Medical Research Archives Open access 2022 0
40 J-LEAPS Vaccines Mature Mouse Bone Marrow Cells to Dendritic Cells-1 (DC1) which can Deliver Protective Immunity Patricia Taylor, Gary K. Koski, Erin B. Bailey et al. · Clinical Immunology 2010 0
41 Su.100. Immunization with a L.E.A.P.S. TM Heteroconjugate Containing the J Peptide from Beta-2 Microglobulin Elicits a T Helper 1 Cytokine Response Patricia Taylor, Daniel H. Zimmerman, Ken S. Rosenthal · Clinical Immunology 2008 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.